Novartis hopeful for novel heart drug

Tuesday 29 August 2017 4 weeks ago 61   Berlin   Print

File Photo.

Report  Web Desk : ZURICH: Novartis will seek regulatory approval this year for a new kind of anti-inflammatory heart drug, though some experts fear fatal infection risks and a high price may overshadow the medicine limited benefits. Keenly awaited clinical trial results released showed heart-attack survivors on one of three doses of canakinumab were 15 percent less likely to suffer another major cardiac event than those on a placebo. Novartis had said in June that the drug met its goal in the study but details were only unveiled at European Society of Cardiology meeting in Barcelona. One leading expert described the benefit as “modest”. Patients getting canakinumab also suffered significantly more deaths from infections than those on placebo – but, on the positive side, they appeared to be at lower risk of cancer. There was no significant difference in the rate of deaths from all causes between the placebo group and those on canakinumab. 02